Trial Profile
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Rexlemestrocel-L (Primary) ; Hyaluronic acid
- Indications Back pain; Intervertebral disc degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Mesoblast
- 30 Jan 2024 According to Mesoblast media release, results from this study will provide FDA with a clinical data package that may result in product approval.
- 09 Jun 2022 According to Mesoblast media release, data from this trial will be presented at Mesoblast Key Opinion Leader Event.
- 11 Jan 2022 According to Mesoblast media release, results from this study were presented at the 2022 Biotech Showcase.